+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ce-141-labeled DOTMP: A theranostic option in management of pain due to skeletal metastases

Ce-141-labeled DOTMP: A theranostic option in management of pain due to skeletal metastases

Journal of Labelled Compounds and Radiopharmaceuticals 62(4): 178-189

Owing to its favorable radioactive decay characteristics (T1/2  = 32.51 d, Eβ [max] = 434.6 keV [70.5%] and 580.0 keV [29.5%], Eγ  = 145.4 keV [48.5%]), 141 Ce could be envisaged as a theranostic radionuclide for use in nuclear medicine. The present article reports synthesis and evaluation of 141 Ce complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP) as a potent theranostic agent targeting metastatic skeletal lesions. Ce-141 was produced with 314 ± 29 MBq/mg (n = 6) specific activity and >99.9% radionuclidic purity (n = 6). Around 185 MBq dose of [141 Ce]Ce-DOTMP was synthesized with 98.6 ± 0.5% (n = 4) radiochemical yield under optimized conditions of reaction, and the preparation showed adequately high in vitro stability. Biodistribution studies in normal Wistar rats demonstrated significant skeletal localization and retention of injected activity (2.73 ± 0.28% and 2.63 ± 0.22% of injected activity per gram in femur at 3 hours and 14 days post-injection, respectively) with rapid clearance from non-target organs. The results of biodistribution studies were corroborated by serial scintigraphic imaging studies. These results demonstrate the potential utility of 141 Ce-DOTMP as a theranostic molecule for personalized patient care of cancer patients suffering from painful metastatic skeletal lesions.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066107228

Download citation: RISBibTeXText

PMID: 30663098

DOI: 10.1002/jlcr.3710

Related references

A "mix-and-use" approach for formulation of human clinical doses of 177 Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases. Journal of Labelled Compounds and Radiopharmaceuticals 60(9): 410-419, 2017

Syntheses and evaluation of 68 Ga- and 153 Sm-labeled DOTA-conjugated bisphosphonate ligand for potential use in detection of skeletal metastases and management of pain arising from skeletal metastases. Chemical Biology and Drug Design 92(3): 1618-1626, 2018

Theranostic Treatment of Metastatic Bone Pain With 177Lu-DOTMP. Clinical Nuclear Medicine 41(12): 966-967, 2016

Synthesis of 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases. Cancer BioTherapy and Radiopharmaceuticals 24(1): 123-128, 2009

Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nuclear Medicine Communications 20(8): 697-702, 1999

Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Supportive Cancer Therapy 3(3): 143-153, 2006

Management of pain in skeletal metastases. Clinical Orthopaedics and Related Research 1995(312): 187-196, 1995

68 Ga]/[ 188 Re] Complexed [CDTMP] Trans-1,2-Cyclohexyldinitrilotetraphosphonic Acid As a Theranostic Agent for Skeletal Metastases. Frontiers in Medicine 4: 72, 2017

Skeletal Localization and Renal Elimination of the Skeletal Targeted Radiotherapeutic , 166Ho-DOTMP. FASEB Journal 18(4-5): Abst 405 13, 2004

Fractionated hemi skeletal irradiation for multi focal skeletal pain in patients with widespread carcinomatous metastases to bone. International Journal Of Radiation Oncology, Biology, Physicspl. 1: 128, 1982

Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer BioTherapy and Radiopharmaceuticals 18(2): 225-230, 2003

Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation. Current Radiopharmaceuticals 11(2): 116-122, 2018

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. Journal of Nuclear Medicine 47(3): 534-542, 2006

The usefulness of 99mTc-HMPAO-labeled leukocyte scintigraphy in the diagnosis of skeletal metastases of cancers. Annals of Nuclear Medicine 14(2): 103-109, 2000

The use of SPECT-CT with 99mTc-labeled phosphates in patients with suspected skeletal metastases in planar bone scintigraphy. Voprosy Onkologii 59(5): 611-619, 2013